What is it about?

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is developing pharmacoeconomics guidelines in different countries in collaboration with experts in those countries. This was one of briefing about development of the Pharmacoeconomics Guidelines for India that is finally released in March 2016.

Featured Image

Why is it important?

Health Technology Assessment is becoming the basis of drug approvals and formulary drug inclusion in most of the countries. Newer way of clinical description of drugs is better explained using outcomes research. To popularize and standardize these new scientific principles, it is highly advisable to have national Pharmacoeconomics and Outcomes Research Guidelines.


I recommend this paper for those who are in the process of making pharmacoeconomics guidelines. Also it would be great for those who want to know the process or key challenges faced while developing the pharmacoeconomics guidelines for India.

Dr Dixon Thomas
Gulf Medical University

Read the Original

This page is a summary of: Development of pharmacoeconomics guidelines for India, Perspectives in Clinical Research, January 2014, Medknow, DOI: 10.4103/2229-3485.128030.
You can read the full text:

Open access logo


The following have contributed to this page